Can you provide the last earnings date for ALNYLAM PHARMACEUTICALS INC?
ALNYLAM PHARMACEUTICALS INC (DUL.DE) last reported earnings on 2/12/2026.
ALNYLAM PHARMACEUTICALS INC (DUL.DE) Earnings History & Surprises
FRA:DUL • US02043Q1076
Current stock price
263.1 EUR
-11.5 (-4.19%)
Last:
DUL.DE Earnings overview
Past quarterly earnings results for ALNYLAM PHARMACEUTICALS INC (DUL.DE), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Apr 29, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $1.03
- Revenue Estimate
- 1.144B
Last Reported
Most Recent- Release Date
- Feb 12, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.82
- EPS Surprise
- -28.48%
- Revenue Surprise
- -8.27%
Beat Rate
Last 8 Quarters 63%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.82 | 1.15 | -28.48% | 226.15% | 1.097B | 1.196B | -8.27% | 84.95% |
| Q3 2025 | 2.11 | 0.76 | 177.15% | 342.53% | 1.249B | 997.35M | 25.23% | 149.35% |
| Q2 2025 | -0.51 | -0.73 | 30.60% | -292.31% | 773.689M | 669.92M | 15.49% | 17.26% |
| Q1 2025 | -0.44 | -1.03 | 57.21% | 15.38% | 594.189M | 597.54M | -0.56% | 20.20% |
| Q4 2024 | -0.65 | -0.64 | -2.21% | 40.91% | 593.166M | 595.47M | -0.39% | 34.90% |
| Q3 2024 | -0.87 | -0.91 | 4.00% | -175.65% | 500.919M | 543.76M | -7.88% | -33.26% |
| Q2 2024 | -0.13 | -1.10 | 88.19% | 94.12% | 659.825M | 452.99M | 45.66% | 106.97% |
| Q1 2024 | -0.52 | -1.21 | 56.90% | 62.86% | 494.333M | 435.88M | 13.41% | 54.82% |
| Q4 2023 | -1.10 | -1.35 | 18.47% | 34.52% | 439.718M | 451.75M | -2.66% | 31.26% |
| Q3 2023 | 1.15 | -1.36 | 184.40% | 142.75% | 750.5M | 391.21M | 91.84% | 183.96% |
| Q2 2023 | -2.21 | -1.40 | -58.30% | 3.49% | 318.8M | 357.52M | -10.83% | 41.81% |
| Q1 2023 | -1.40 | -1.80 | 22.24% | 30.00% | 319.3M | 318.5M | 0.25% | 49.70% |
| Q4 2022 | -1.68 | -1.91 | 12.09% | 22.22% | 335M | 319.4M | 4.88% | 29.59% |
| Q3 2022 | -2.69 | -1.78 | -51.47% | -64.02% | 264.3M | 297.59M | -11.19% | 40.88% |
| Q2 2022 | -2.29 | -1.66 | -37.75% | -42.24% | 224.8M | 261M | -13.87% | 1.90% |
| Q1 2022 | -2.00 | -1.88 | -6.57% | -16.96% | 213.3M | 248.24M | -14.08% | 20.10% |
| Q4 2021 | -2.16 | -1.57 | -37.46% | -3.35% | 258.5M | 238.3M | 8.48% | 58.01% |
| Q3 2021 | -1.64 | -1.60 | -2.56% | 24.77% | 187.6M | 223.07M | -15.90% | 49.01% |
| Q2 2021 | -1.61 | -1.65 | 2.16% | -3.21% | 220.6M | 196.66M | 12.17% | 112.12% |
| Q1 2021 | -1.71 | -1.76 | 3.03% | 6.56% | 177.6M | 172.11M | 3.19% | 78.49% |
| Q4 2020 | -2.09 | -1.74 | -19.89% | - | 163.6M | 149.74M | 9.26% | - |
| Q3 2020 | -2.18 | -1.67 | -30.49% | - | 125.9M | 123.17M | 2.22% | - |
| Q2 2020 | -1.56 | -1.75 | 10.74% | - | 104M | 101.47M | 2.49% | - |
| Q1 2020 | -1.83 | -1.92 | 4.60% | - | 99.5M | 93.552M | 6.36% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
59.12%
Max EPS beat (4)
177.15%
Min EPS beat (4)
-28.48%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
7.97%
Max Revenue beat (4)
25.23%
Min Revenue beat (4)
-8.27%
Analysis
In the last 4 quarters, DUL.DE has beaten EPS estimates in 3 out of 4 releases
DUL.DE has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, DUL.DE has beaten the EPS estimates by 59.1% on average.
In the last 4 quarters, DUL.DE has beaten the revenue estimates by 8.0% on average.
Related analysis
ALNYLAM PHARMACEUTICALS INC / DUL.DE Earnings FAQ
Did ALNYLAM PHARMACEUTICALS INC (DUL.DE) beat earnings estimates last quarter?
ALNYLAM PHARMACEUTICALS INC (DUL.DE) missed EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does DUL stock beat earnings estimates?
In the last 4 quarters, ALNYLAM PHARMACEUTICALS INC (DUL.DE) has beaten EPS estimates in 3 out of 4 releases.